Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.14 0.31 −4.16%
Market cap
$487.1M
P/E
57.3×
Fwd P/E
−2.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 63.92
P/S ratio
2.00 3.20 7.59 1.70
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(10.55) (27.66) (9.80) (11.15)
P/B ratio
1.11 1.94 1.75 0.96
EV/Sales
(0.52) 0.60 0.73 (0.09)
EV/EBITDA
1.53 0.00 0.00 1.56
EV/FCF
0.49 (0.57) (0.25) 0.13
Current Ratio
5.70 4.92 5.44 7.91
Net Debt/EBITDA
17.42 9.06 9.59 (3.40)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(9.51%) (10.79%) (31.32%) 1.56%
Free Cash Flow Yield
(52.83%) (32.79%) (37.87%) (38.78%)
Free Cash Flow per Share
(0.81) (0.43) (1.10) (0.75)
Book value per Share
7.71 6.12 6.04 8.68
Free Cash Flow
(59.20) (30.60) (70.50) (48.50)
EV/EBIT
1.59 0.00 0.00 1.54
Other line items

Show all line items

Columns are period end dates